toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
  Record Links
Author Anhoj, J.; Bisgaard, A.M.; Bisgaard, H. url  openurl
  Title Systemic activity of inhaled steroids in 1- to 3-year-old children with asthma Type Journal Article
  Year (down) 2002 Publication Pediatrics Abbreviated Journal Pediatrics  
  Volume 109 Issue 3 Pages E40  
  Keywords Administration, Inhalation; Androstadienes/adverse effects/*therapeutic use; Asthma/*drug therapy/physiopathology; Bronchodilator Agents/adverse effects/*therapeutic use; Budesonide/adverse effects/*therapeutic use; Child, Preschool; Cross-Over Studies; Double-Blind Method; Fluticasone; Growth/drug effects; Humans; Infant; Leg/*growth & development; Nebulizers and Vaporizers  
  Abstract OBJECTIVE: To study the systemic activity of inhaled steroids in young children. METHODS: Forty children with mild asthma aged 1 to 3 years were studied in a 3-way crossover, randomized, placebo-controlled, double-blind trial. Treatment with inhaled fluticasone propionate, 200 microg twice daily delivered via pressurized metered-dose inhaler (pMDI) and Babyhaler (FP400), was compared with budesonide, 200 microg twice daily delivered via pMDI and NebuChamber (BUD400), and to placebo. The Babyhaler was primed before use. Knemometry was used to detect systemic steroid activity. It was performed with a hand-held knemometer after 1 and 4 weeks of treatment. The increase in lower-leg length within this 3-week period was used as the outcome measure. The intention-to-treat population was analyzed by analysis of variance. RESULTS: The increases in the lower-leg length during placebo, BUD400, and FP400 treatments were 85, 45, and 34 microm/d, respectively (adjusted mean). The growth in lower-leg length was significantly reduced from both steroid treatments. The difference between BUD400 and placebo was -40 microm/d (n = 25; 95% confidence interval [CI]: -8 to -72). The difference between FP400 and placebo was -51 microm/d (n = 26; 95% CI: -19 to -83). The difference between FP and BUD was -11 microm/d and was not statistically significant (n = 28; 95% CI: 20 to -42). CONCLUSION: FP and BUD are both systemically active in children 1 to 3 years old when administered for 4 weeks from their dedicated spacer devices in daily doses of 400 microg with no difference between the 2 steroid regimens. These findings call for studies of clinical side effects from these treatments of preschool children.  
  Address Pulmonary Service, Department of Paediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark  
  Corporate Author Thesis  
  Impact Factor 05,473 First Author Anhoj, J. Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Senior Author Bisgaard, H.  
  ISSN 0031-4005 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:11875168 Approved no  
  Call Number Serial 156  
Permanent link to this record
Select All    Deselect All
 |   | 

Save Citations:
Export Records: